拟探究鼠李糖乳杆菌JS-SZ-2-1抗幽门螺杆菌(Helicobacter pylori)感染的作用效果。首先评价了鼠李糖乳杆菌JS-SZ-2-1体外抑制H.pylori生长和降低其黏附的能力,再进一步进行临床效果评价。临床研究招募了26名H.pylori阳性患者,随机分为2组:安慰剂和鼠李糖乳杆菌JS-SZ-2-1组,患者服用菌粉1天2次,为期1个月。结果表明,鼠李糖乳杆菌JS-SZ-2-1体外抑菌和降低H.pylori黏附的效果显著,且相较于安慰剂组,鼠李糖乳杆菌JS-SZ-2-1显著降低了临床患者14C呼气值(urea breath test,△UBT=106.00)和胃肠症状评分(P<0.05)。与此同时,鼠李糖乳杆菌对患者的肠道菌群有一定的调节作用,然而患者血清胃蛋白酶原(pepsinogen,PG)水平和IL-8、TNF-α免疫因子水平无明显变化。这些结果表明,鼠李糖乳杆菌JS-SZ-2-1能够有效地降低患者体内H.pylori定殖量并改善胃肠症状。
This study was conducted to investigate the effect ofLactobacillus rhamnosus JS-SZ-2-1 againstHelicobacter pyloriinfection.L.rhamnosusstrains were tested for their ability to inhibit the growth ofH.pylorias well as to reduce the adhesion ofH.pylorito gastric epithelial cellin vitro,and then the clinical effect was further investigated.Twenty-sixH.pylori-positive patients were recruited and randomly divided into 2 groups:placebo group andL.rhamnosus JS-SZ-2-1 group.Probiotic powder was given twice a day to volunteers for one month and then the indicators were tested.In vitro results showed thatL.rhamnosus JS-SZ-2-1 significantly inhibited the growth ofH.pylori and the adhesion ofH.pylori to AGS.Compared to placebo group,Lactobacillusstrains can alleviate H pyloriinfection by reducing the value of 14C-urea breath test (UBT,△UBT=106.00) and gastrointestinal symptom rating scale (GSRS,P<0.05).Besides,there was a significant alteration in the structure of intestinal flora,while no significant changes were found in the serum levels of pepsinogen,IL-8 and TNF-α.No adverse reactions occurred in the process of probiotic intervention.These results suggested thatL.rhamnosus JS-SZ-2-1 may alleviate H.pyloriinfection and improve the value of GSRS.
[1] GO M F.Review article:natural history and epidemiology ofHelicobacter pyloriinfection[J].Alimentary Pharmacology and Therapeutics,2002,16:3-15.
[2] COVER T L,BLASER M J.Helicobacter pyloriin health and disease[J].Gastroenterology,2009,136(6):1 863-1 873.
[3] TONG J,RAN Z,SHEN J,et al.Meta-analysis:The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylorieradication therapy[J].Alimentary Pharmacology and Therapeutics,2007,25(2):155-168.
[4] GRAHAM D Y,FISCHBACH L.Helicobacter pylori treatment in the era of increasing antibiotic resistance[J].Gut,2010,59(8):1 143-1 153.
[5] SREEJA P S,ARUNACHALAM K,SAIKUMAR S,et al.Gastropropective effect and mode of action of methanol extract ofSphenodesme involucrata var.paniculate (CB Clarke) munir (Lamiaceae) leaves on experimental gastric ulcer models[J].Biomedicine and Pharmacotherapy,2018,97:1 109-1 118.
[6] 陈晓华.拮抗幽门螺杆菌益生菌的筛选及其干预机制的研究[D].无锡:江南大学,2011.
CHEN X H.Screening of probiotics with antagonistic activities againstHelicobacter pylori and the study of intervention mechanisms[D].Wuxi:Jiangnan University,2011.
[7] 潘明芳.植物乳杆菌ZDY2013对小鼠胃肠道微生态的影响及其对幽门螺杆菌感染的预防作用[D].南昌:南昌大学,2016.
PAN M F.Modulation of the mice gastrointestinal microbiota by Lactobacilus plantarumZDY 2013 and its preventive effects againstHelicobacter pylori infection[D].Nanchang:Nanchang University,2016.
[8] EMARA M H,MOHAMED S Y,ABDEL-AZIZ H R,et al.Lactobacillus reuteri in management ofHelicobacter pylori infection in dyspeptic patients:a double-blind placebo-controlled randomized clinical trail[J].Therapeutic Advances in Gastroenterology,2014,7(1):4-13.
[9] WESTERIK N,REID G,SYBESMA W,et al.The probioticLactobacillus rhamnosus for alleviation ofHelicobacter pylori-associated gastric pathology in East Africa[J].Frontiers in Microbiology,2018,9:1 873-1 884.
[10] RYAN K A,PAUL D,YIN L,et al.Strain-specific inhibition ofHelicobacter pylori byLactobacillus salivariusand other Lactobacilli[J].Journal of Antimicrobial Chemotherapy,2008,61(4):831-834.
[11] PASTENE E,PARADA V,AVELLO M,et al.Catechin-based procyanidins fromPeumus boldus MO1.aqueous extrat inhibitHelicobacter pyloriurease and adherence to adenocarcinoma gastric cells[J].Phytotherapy Research,2014,28(11):1 637-1 645.
[12] SVEDLUND J,SIODIN I,DOTEVALL G.GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndronme and peptic ulcer disease[J].Digestive Diseases and Sciences,1988,33(2):129-134.
[13] MAO B,LI D,ZHAO,et al.Metagenomic insights into the effects of Fructo-Oligosaccharides (FOS) on the composition of fecal microbiota in mice[J].Journal of Agricultural and Food Chemistry,2015,63(3):856-863.
[14] ZHENG P X,FANG H Y,YANG H B,et al.Lactobacillus pentosus strain LPS16 produces lactic acid,inhibiting multidrug-resistantHelicobacter pylori[J].Journal of Microbiology Immunology and Infection,2016,49(2):168-174.
[15] MUKAI T.Inhibition of binding ofHelicobacter pylorito the glycolipid receptors by probiotic Lactobacillus reuteri[J].FEMS Immunology and Medical Microbiology,2002,32(2):105-110.
[16] KLERK N D,MAUDSDOTTER L,GEBREEGZIABHER H,et al.Lactobacillireduce Helicobacterattachment to host gastric epithelial cells by inhibiting adhesion gene expresion[J].Infection and Immunity,2016,84(5):1 526-1 535.
[17] GRAHAM D Y,KLEIN P D.Accurate diagnosis ofHelicobacter pylori[J].Journal of Gastroenterology and Hepatology,2000,29(4):885-893.
[18] ZAGARI P M,POZZATO P,MARTUZZI C,et al.13C-urea breath test to assess Helicobacter pyloribacterial load[J].Helicobacter,2005,10(6):615-619.
[19] CRUCHET S,OBREGON M C,SALAZAR G,et al.Effect of ingestion of dietary product containingLactobacillus johnsonii Lal onHelicobacter pyloricolonization in children[J].Nutrition,2003,19(9):716-721.
[20] LEE C,SHIN H,YU M,et al.Evaluation of the potential inhibitory activity of a combination ofL.acidophilus,L.rhamnosus andL.sporogenes onHelicobacter pylori:A randomized double-blind placebo-controlled clinical trail[J].Chinese Journal of Integrative Medicine,2017,23(3):176-182.
[21] FRANCAVILLA R,LIONETTI E,CASTELLANETA S P,et al.Inhibition of Helicobacter pylori infection in humans byLactobacillus reuteriATCC 55730 and effect on eradication therapy:A pilot study[J].Helicobacter,2008,13(2):127-134.
[22] MIKI K,URITA Y,LSHIKAWA F,et al.Effect ofBifidobacterium bifodum fermented milk on Helicobacter pyloriand serum pepsinogen levels in humans[J].Journal of Dairy Science,2007,90(6):2 630-2 640.
[23] FRANCAVILLA R,POLIMENO L,DEMICHINA A,et al.Lactobacillus reuteri strain combination inHelicobacter pylori infection:a randomized,double-blind,placebo-controlled study[J].Journal of Clinical Gastroenterology,2014,48(5):407-413.
[24] IGARASHI M,NAGANO J,TSUDA A,et al.Correlation between the serum pepsinogen Ⅰ level and the symptom degree in proton pump inhibitor-users administered with a probiotic[J].Pharmaceuticals,2014,7(7):754-764.
[25] KUSTERS J G,VLIET V,KUIPERS E J.Pathogenesis ofHelicobacter pylori infection[J].Clinical Microbiology Reviews,2006,19(3):449-490.
[26] BOLTIN D.Probiotics in Helicobacter pylori-induced peptic ulcer disease[J].Best Practice and Research Clinical Gastroenterology,2016,30(1):99-109.
[27] CHEN Y,WU H,WU S,et al.Parasutterella,in association with irritable bowel syndrome and intestinal chronic inflammation[J].Journal of Gastroenterology and Hepatology,2018,33(11):1 844-1 852.
[28] WANG P,GAO J,KE W,et al.Resveratrol reduces obesity in high-fat diet-fed mice via modulating the structure and metabolic function of the gut microbiota[J].Free Radical Biology and Medicine,2020,156:83-98.
[29] SINGH H,TORRALBA M G,MONCERA K J,et al.Gastro-intestinal and oral microbiome signatures associated with healthy aging[J].Geroscience,2019,41(6):907-921.
